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INTRODUCTION
Azoospermia affects up to 1% of men in the general population and represents the major cause of male infertility (Miyamoto et al., 2015; Song et al., 2016; Mitchell et al., 2017) .
Although obstruction of the excurrent ducts is known to result in azoospermia, this abnormality accounts for less than half of all cases (Jarow et al., 1989 ; Practice Committee of American Society for Reproductive Medicine in collaboration with Society for Male Reproduction and Urology, 2008) . Nonobstructive azoospermia is a multifactorial disorder caused by genetic, epigenetic, and environmental factors (Venkatesh et al., 2014) . To date, mutations in multiple genes have been reported to cause non-obstructive azoospermia without additional clinical features (idiopathic non-obstructive azoospermia). In 2012, Miyamoto et al. and Massart et al. reviewed previous studies and each compiled a list of genes associated with idiopathic non-obstructive azoospermia Miyamoto et al., 2012) . Subsequently, several other genes including TEX11 have been reported as possible causes of azoospermia (Ayhan et al., 2014; Ge et al., 2015; Yatsenko et al., 2015; Miyamoto et al., 2016) . However, there has been no report of comprehensive mutation screening of these genes; therefore, the clinical significance of monogenic mutations in the etiology of idiopathic non-obstructive azoospermia remains uncertain (Mitchell et al., 2017) . Similarly, although previous studies identified multiple submicroscopic copy-number variations (CNVs), particularly those on the sex chromosomes, in patients with non-obstructive azoospermia (T€ uttelmann et al., 2011; Krausz et al., 2012; Stouffs et al., 2012; Lopes et al., 2013; Eggers et al., 2015) , the contribution of CNVs to the disease phenotype remains to be confirmed in future studies.
The aim of this study was to clarify the contribution of nucleotide substitutions in known causative genes and submicroscopic CNVs in the genome to the development of non-obstructive azoospermia. To this end, we employed a gene panel approach via next-generation sequencing (NGS) and genome-wide copynumber analysis using array-based comparative genomic hybridization (CGH).
MATERIALS AND METHODS

Patients
Our study group consisted of 40 Japanese patients with idiopathic non-obstructive azoospermia (Table S1 ). These patients were recruited in our previous study (Saito et al., 2015) , which involved copy-number analysis of Y chromosomal AZF (Azoospermia factor) regions. All patients manifested infertility and were diagnosed with non-obstructive azoospermia based on the guidelines of the World Health Organization (World Health Organization, 2010) . Patients with additional clinical features or cytogenetically detectable chromosomal abnormalities and those with a history of specific disorders or chemical exposures that may affect spermatogenesis were excluded. We also excluded patients with homozygous or compound heterozygous substitutions in CFTR, which are known to underlie obstructive azoospermia (Chill on et al., 1995) . Detailed information on blood hormone measurements and testicular histology was available for 19 patients (Table S1 ).
In our previous study, the patients underwent multiplex ligation-dependent probe amplification (MLPA) analysis for the AZF regions (Saito et al., 2015) . Of the 40 patients, 17 carried a simple 'gr/gr deletion', an apparently benign CNV in the Japanese population, whereas six carried other AZF-linked CNVs (Table S1 ). In particular, patient 7 carried a~4 Mb duplication involving the AZFbc region, which has been associated with the risk of azoospermia (Saito et al., 2015) . The remaining 17 patients were free from copy-number alterations in the AZF regions.
Ethical approval
This study was approved by the Institutional Review Board Committee at the National Center for Child Health and Development and performed after obtaining written informed consent from the participants.
Detection of nucleotide substitutions
Mutation screening was carried out for 25 genes associated with non-obstructive azoospermia, namely , ART3, BPY2, DBY,  DNMT3L, FKBP6, FKBPL, MEI1, MSH4, PARP2, PLK4, PRDM9,  PYGO2, RBMY, SEPTIN12, SOHLH1, SPATA17, STRA8, SYCP3,  TAF4B, TAF7L, TEX11, UBR2, USP9Y, ZMYND15 , and ZNF230. Of these, 20 genes were listed by Miyamoto et al. (2012) and/ or by Massart et al. (2012) , while five genes were recently associated with non-obstructive azoospermia (Ayhan et al., 2014; Ge et al., 2015; Yatsenko et al., 2015; Miyamoto et al., 2016) . The coding regions and exon-intron boundaries of the target genes were analyzed by NGS-based amplicon sequencing. Genomic DNA was extracted from peripheral blood cells using standard protocols. DNA libraries were constructed using a custom-made HaloPlex Target Enrichment System that targets 490 disease-associated genes (Design ID 20669-1446019260 and 20669-1370918756 ; Agilent Technologies, Palo Alto, CA, USA). Our design covered approximately 98.8% of the target regions. DNA libraries were sequenced on a HiSeq sequencer (Illumina, San Diego, CA, USA) with~50 samples per lane of a flow cell, resulting in 100-or 150-bp paired-end reads. We used a HiSeq Rapid SBS Kit v2 (Illumina) and HiSeq PE Rapid Cluster Kit v2 (Illumina) for sequencing. Image analysis was performed using the HISEQ CONTROL Software (version 2.2.68, Illumina). Base calling and quality scoring were performed using REAL TIME ANALYSIS Software (version 1.18.66.3, Illumina). The resultant base call files were converted to FASTQ files using the BCL2FASTQ CONVERSION Software (version 1.8.4, Illumina).
Sequence reads were processed, mapped, and analyzed as described previously (Fukawatase et al., 2014) . In brief, the paired-end reads were first trimmed by removing restriction enzyme sites and low-quality bases at both ends and then aligned to the hs37d5 sequence (GRCh37 and decoy sequences) using the Burrows-Wheeler Aligner 0.7.13. Uniquely mapped reads were selected by a custom script and converted from SAM to BAM files using SAMtools 1.3. Genome Analysis Toolkit (GATK) 3.5 was then used to produce calibrated BAM files for each sample. The annotated VCF files were then filtered using GATK with a stringent filter setting and custom scripts. We excluded calls with low quality scores, that is, single nucleotide polymorphisms (SNPs) where Quality <30.0, QualityDepth <2.0, RMSMappingQuality <40.0, FisherStrand >60.0, or HaplotypeScore >13.0, and indels where Quality <10.0, QualityDepth <2.0, RMSMappingQuality <40.0, FisherStrand >200.0, or HaplotypeScore >13.0. Variants were functionally annotated using ANNOVAR (2016Feb01 version).
Next, we analyzed nucleotide changes in the 25 target genes. We focused on non-synonymous substitutions in the coding regions and intronic substitutions at splice sites. SNPs with allele frequencies of more than 1.0% in the Japanese general population (dbSNP, https://www.ncbi.nlm.nih.gov/) were excluded from further analyses. All substitutions that may be associated with the disease were subjected to Sanger direct sequencing. Primer sequences are available upon request.
Characterization of nucleotide substitutions
Functional consequences of missense substitutions were examined by five in silico programs, namely, Polymorphism Phenotyping v2 (PolyPhen-2, http://genetics.bwh.harvard.edu/ pph2/), Sorting Intolerant From Tolerant (SIFT, http://sift.jcvi. org/), Combined Annotation Dependent Depletion (CADD, http://cadd.gs.washington.edu), Mendelian Clinically Applicable Pathogenicity (M-CAP, http://bejerano.stanford.edu/mcap/inde x.html) and MutationTaster (http://www.mutationtaster.org/). In this study, PolyPhen-2 scores of >0.8, SIFT scores of <0.05, CADD scores of >20, M-CAP scores of >0.025, or MutationTaster results of 'disease causing' were considered to be signs of damaging variants. In addition, the effects of substitutions at exonintron boundaries on splicing were assessed using GENSCAN (http://genes.mit.edu/GENSCAN.html), NNSPLICE (http:// www.fruitfly.org/seq_tools/splice.html), and NetGene2 (http:// www.cbs.dtu.dk/services/NetGene2/).
We classified nucleotide changes into three groups: (i) putative pathogenic mutations: mutations that have previously been identified in patients with non-obstructive azoospermia or hitherto unreported missense substitutions that were assessed as 'probably damaging' or 'possibly damaging' by multiple in silico programs; (ii) rare SNPs possibly associated with disease risk: rare substitutions that have previously been submitted to SNP databases and were assessed as 'probably damaging' or 'possibly damaging' by multiple in silico programs; and (iii) probable neutral variants: nucleotide substitutions that were predicted to be 'benign' by most of the five in silico programs.
Next, we compared allele frequencies of the variants in our patient group with those in the general population of the 1000 genomes (dbSNP, https://www.ncbi.nlm.nih.gov/), the Human Genetic Variation Database (HGVD, http://www.hgvd.genome. med.kyoto-u.ac.jp/), the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org/), and Exome Sequencing Project 6500 (ESP6500, http://evs.gs.washington.edu/EVS/).
Statistical analysis
The statistical significance of the comparison of allele frequency in the patient group and the general population was evaluated using v 2 and Fisher's exact probability tests.
Detection of CNVs
CNVs in the genome were screened by array CGH using catalog human arrays (4 9 180 k format, catalog number G4449A; or 8 9 60 k format, catalog number G4450A, Agilent Technologies). The 4 9 180 k array was used in eight of 40 patients, while the remaining 32 patients were analyzed with the 8 9 60 k array. The 4 9 180 k array comprised 170,334 oligonucleotide probes with a median probe spacing of~13 kb. The smallest detectable CNV was estimated to be~25 kb. The 8 9 60 k array comprised 55,077 oligonucleotide probes with a median probe spacing of~41 kb. The smallest detectable CNV was predicted to be~70 kb. The data were analyzed using DNA Analytics (version 7.0.4.0, Agilent Technologies) with the ADM-2 algorithm at a threshold of 6.0. Aberrant signals of three or more adjacent probes were interpreted as a sign of a CNV. We referred to the Database of Genomic Variants (http://projects.tcag.ca/vari ation/) to exclude benign CNVs, and the UCSC genome browser (https://www.genome.ucsc.edu/) to determine genes affected by each CNV.
RESULTS
Detection and characterization of nucleotide substitutions
We obtained 16,411,378 total reads for the target regions. The average depth for the target regions was 289.9. A total of 521 nucleotide changes were identified in the target regions (Figure S1 and Table S2A ). Of these, 509 variants were excluded from further analyses ( Figure S1 and Table S2B,C): 429 were located outside of coding regions and exon-intron boundaries, 41 were synonymous substitutions, five were assessed as probable sequence errors, 29 accounted for more than 1% of the general population, and three were not reproduced by Sanger sequencing. We also excluded two heterozygous substitutions in , 2014) . Consequently, we focused on remaining 12 variants found in 10 patients. These 12 variants consisted of four putative pathogenic mutations, four rare SNPs possibly associated with disease risk, and four probable neutral variants (Tables 1-4 , Fig. 1A , and Figure S2A-C) .
Putative pathogenic mutations were identified in patients 1-5. The mutations were a heterozygous splice acceptor site mutation in SOHLH1, a hemizygous missense mutation in TEX11, a heterozygous splice donor site mutation in SPATA17, and a heterozygous missense mutation in STRA8 (Table 1, Fig. 1A , and Figure S2A ). Of these, the mutations in SOHLH1 and TEX11 were previously identified in patients with non-obstructive azoospermia (Choi et al., 2010; Yatsenko et al., 2015) and in an extremely small percentage of the general population (Table 2) , while the other mutations were first identified in the present study. The c.346-1G>A mutation in SOHLH1 was shared by two cases (patients 1 and 2) and was predicted to lead to skipping of exon 4 or activation of a cryptic splice acceptor site in exon 4 (Table 4) . 
washington.edu/EVS/).
h Although the GG genotype at the c.608A/G polymorphism of SPATA17 were found to be more common in 18 patients with mitotic arrest than in 96 controls (Miyamoto et al., 2009) , the mode of inheritance of this gene remains uncertain. f MutationTaster (http://www.mutationtaster.org/). g Although the GG genotype at the c.608A/G polymorphism of SPATA17 were found to be more common in 18 patients with mitotic arrest than in 96 controls (Miyamoto et al., 2009) , the mode of inheritance of this gene remains uncertain.
h Single nucleotide polymorphism (SNP) possibly associated with disease risk. This mutation has previously been shown to cause an inframe deletion of SOHLH1 in cultured cells (Choi et al., 2010) . The remaining mutations were each detected in a single case. The c.872+1G>A mutation in SPATA17 was predicted to disrupt the splice donor site of exon 8 (Table 4 ). The c.C74T, p.(Thr25Ile) in STRA8 was assessed as damaging by three in silico programs (Table 3) .
Rare SNPs possibly associated with disease risk were identified in patients 3, 4, 6, and 7. The four SNPs comprised heterozygous missense and splice acceptor site substitutions in MEI1 and heterozygous missense substitutions in ART3 and SPATA17 (Table 1 and Figure S2B ). These variants were assessed as damaging by most in silico analyses (Table 3 ). The substitutions in ART3 and SPATA17 and c.C1223G, p.(Thr408Arg) in MEI1 were 828 Andrology, 2017, 5, 824-831 identified in our patient group at frequencies similar to those in the general population, while the frequency of c.734-2A>C in MEI1 in the general population remained unknown ( Table 2 ). The c.734-2A>C mutation in MEI1 was predicted to cause skipping of exon 7 (Table 4) . Probable neutral variants were found in patients 6 and 8-10. These variants were heterozygous missense substitutions in UBR2, PRDM9, MSH4 and PLK4 (Table 1 and Figure S2C ). These variants were detected in the patient group and in the general population at similar frequencies ( Table 2) .
Detection of CNVs
Five CNVs, in addition to a previously recognized Y chromosomal microduplication in patient 7, were identified in five patients (patients 7, 9, and 11-13; Tables 1 and 5, and Fig. 1B) . The five CNVs were copy-number gains at 1q, 5q, Xp, 18q and Xq. These CNVs have not been associated with azoospermia. These CNVs involved multiple genes (Table 5 and Fig. 1B ). In particular, the copy-number gain on 5q encompasses PELO (Shamsadin et al., 2000) , a human homolog of a spermatogenic gene in drosophila, and that on 18q harbors PHLPP1, a gene strongly expressed in the testis (Nagase et al., 1998) .
DISCUSSION
Mutation analysis of 25 genes identified putative pathogenic mutations in five of 40 (12.5%) cases with non-obstructive azoospermia. These mutations included a heterozygous splice acceptor site substitution in SOHLH1 (c.346-1G>A) and a hemizygous missense substitution in TEX11 [c. A511G, ], both of which have been reported as causes of nonobstructive azoospermia (Choi et al., 2010; Yatsenko et al., 2015) . It has been shown that c.346-1G>A in SOHLH1 results in aberrant splicing and that c.A511G in TEX11 affects protein structure (Choi et al., 2010; Yatsenko et al., 2015) . These findings provide further evidence of the significant roles of SOHLH1 and TEX11 in spermatogenesis. Additionally, we identified a novel 'probably damaging' heterozygous mutation in STRA8 [c. C74T, p.(Thr25Ile) ]. This substitution likely underlies the disease of patient 5, because heterozygous mutations in STRA8 have been associated with spermatogenic failure (Miyamoto et al., 2002; Lu et al., 2013) . Moreover, a heterozygous splice donor site substitution (c.872+1G>A) in SPATA17, a putative spermatogenic gene (Miyamoto et al., 2009) , was detected in patient 4. We cannot exclude the possibility that this substitution have played a role in the development of azoospermia in patient 4. The mode of inheritance of SPATA17 substitutions remains unknown, although the GG genotype at the c.608A/G polymorphism of this gene were found to be more common in 18 patients with mitotic arrest than in 96 controls (Miyamoto et al., 2009) . Collectively, the results of this study indicate that single-gene mutations underlie a certain fraction of cases with idiopathic non-obstructive azoospermia.
In addition, patients 3, 4, 6, and 7 carried rare SNPs possibly associated with disease risk. The heterozygous SNPs in MEI1, ART3, and SPATA17 may have exerted deleterious effects on spermatogenesis, because these SNPs were predicted to be 'probably damaging' and affect proteins involved in spermatogenesis. Indeed, previous studies have suggested that MEI1 and ART3 mutations are associated with the risk of azoospermia in an autosomal dominant manner (Sato et al., 2006; Okada et al., 2008; Lin et al., 2015) . However, frequencies of these substitutions in our patient group, except for a splice site substitution in MEI1, were comparable with those in the control population, these variations may be functionally neutral polymorphisms. Alternatively, these variants may increase the risk of the disease in individuals with high susceptibility. In addition, we identified probable neutral variants in UBR2, PLK4, PRDM9, and MSH4, whose contributions to disease risk are unclear.
Array-CGH identified heterozygous submicroscopic CNVs in four patients, in addition to one previously recognized pathogenic CNV on the Y chromosome. The X chromosomal and autosomal CNVs encompassed several genes and have not been reported previously. We could not exclude the possibility that these CNVs are associated with azoospermia. In particular, the copy-number gains on 5q and on 18q harboring testis-associated genes may have some effects on spermatogenesis (Nagase et al., 1998; Shamsadin et al., 2000) . Furthermore, the frequency of CNVs may be underestimated in this study, because microarrays used in this study had relatively low resolutions. To date, multiple X chromosomal and autosomal CNVs have been identified in patients with azoospermia (T€ uttelmann et al., 2011; Krausz et al., 2012; Stouffs et al., 2012; Lopes et al., 2013; Eggers et al., 2015) . The clinical significance and disease-causative mechanisms of each azoospermia-associated CNV needs to be clarified in future studies.
Notably, five patients had multiple mutations and/or CNVs. In particular, patient 4 carried heterozygous splice site substitutions both in SPATA17 and MEI1, and patient 7 with a rare SPATA17 SNP also had a submicroscopic Y chromosomal CNV. These findings suggest for the first time that non-obstructive azoospermia can arise from oligogenic mutations. To date, a few congenital disorders, such as non-syndromic hypospadias and hypogonadotropic hypogonadism, are known to have oligogenic origins (Sykiotis et al., 2010; Kon et al., 2015) . Non-obstructive 
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NEXT-GENERATION SEQUENCING FOR PATIENTS azoospermia may represent a novel example of oligogenic human disorders. This study has some limitations. First, the number of participants was small. Thus, rare pathogenic mutations and CNVs may have been missed in this study. Second, this study consisted of only Japanese participants. As the underlying factors of nonobstructive azoospermia appear to vary among ethnic groups (Sato et al., 2006; Massart et al., 2012; Lin et al., 2015) , our results may not be simply applicable to other populations. Third, we did not examine parental samples of the mutation-positive patients, although molecular analysis of the patients' fathers would be useful for confirming the pathogenicity of mutations. Lastly, clinical information of the patients was limited. Further studies are necessary to clarify genotype-phenotype correlation of each monogenic mutation and CNV.
CONCLUSIONS
The results of this study indicate that monogenic and oligogenic mutations, including those in SOHLH1 and TEX11, account for more than 10% of cases with idiopathic nonobstructive azoospermia. Furthermore, this study identified several substitutions in other genes as well as submicroscopic X chromosomal and autosomal CNVs, whose contribution to the disease risk needs to be evaluated in future studies.
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